- 询价
- Biogradetech
- 美国
- BGT-ANT-39501-50ug
- 2025年07月15日
- 查看datasheet
企业认证
相关产品推荐更多 >
CRYAB单克隆抗体, 克隆号3A10.H4/CRYAB单克隆抗体, 克隆号3A10.H4/CRYAB单克隆抗体, 克隆号3A10.H4
询价
CDK7单克隆抗体, 克隆号MO-1/CDK7单克隆抗体, 克隆号MO-1/CDK7单克隆抗体, 克隆号MO-1
询价
SART2 polyclonal antibody (A01)/SART2 polyclonal antibody (A01)/SART2 polyclonal antibody (A01)
询价
GABARAPL1 多克隆抗体
询价
C20orf132 purified MaxPab mouse polyclonal antibody (B01P)/C20orf132 purified MaxPab mouse polyclonal antibody (B01P)/C20orf132 purified MaxPab mouse polyclonal antibody (B01P)
询价
万千商家帮你免费找货
0 人在求购买到急需产品
- 详细信息
- 文献和实验
- 技术资料
- 保存条件：
查看datasheet
- 保质期：
1年
- 级别：
科研级别
- 库存：
100
- 供应商：
艾美捷科技
- 应用范围：
查看datasheet
- 抗体英文名：
Cytokeratin 18 Monoclonal Antibody (1B3)
- 抗体名：
Cytokeratin 18 Monoclonal Antibody (1B3)
Cytokeratin 18 Monoclonal Antibody (1B3)，Cytokeratin 18 Monoclonal Antibody (1B3)，
产品名称：Cytokeratin 18 Monoclonal Antibody (1B3)-Cytokeratin 18 Monoclonal Antibody (1B3)
产品货号：BGT-ANT-39501-50ug
产品规格：50ug
应用类型：Cytokeratin 18 Monoclonal Antibody (1B3)产品详情查看提供的产品datasheet。
Cytokeratin 18 Monoclonal Antibody (1B3),Cytokeratin 18 Monoclonal Antibody (1B3)
Cytokeratin 18 Monoclonal Antibody (1B3)-Cytokeratin 18 Monoclonal Antibody (1B3)Cytokeratin 18 Monoclonal Antibody (1B3)产品保存方式查看提供的产品datasheet。
点击：Cytokeratin 18 Monoclonal Antibody (1B3)-Cytokeratin 18 Monoclonal Antibody (1B3)更多Biogradetech产品信息价格，货期，产品说明，百度搜“艾美捷科技”进入官网网站，查看具体产品且快速下单。
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验【翻译】Development trends for monoclonal antibody cancer therapeutics
). However, since 2000, humanized and human mAbs have been entering clinical study at approximately the same rate (4.3 versus 4.5 mAbs per year, respectively). Figure 1 | Categories of monoclonal antibody cancer therapeutics entering clinical study during 1980–1989
Technology and Production of Murine Monoclonal and Recombinant Antibodies and Antibody Fragments
production described by K�hler and Milstein in 1975 (1 ). In the last 30 yr a number of genetically engineered antibody constructions have emerged, including chimeric and human-like antibodies as well as different antibody fragments. Nowadays, 18 rnAb
In the field of therapeutic recombinant proteins, monoclonal antibodies (mAbs) have achieved a rising success with more than 30 mAbs that have reached the market in the past 20 years. From a structural standpoint, one of the most important
技术资料暂无技术资料 索取技术资料
